Relay Therapeutics Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Relay Therapeutics Inc 公司

Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.

Relay Therapeutics Inc简介



公司代码RLAY

公司名称Relay Therapeutics Inc

上市日期Jul 16, 2020

CEOPatel (Sanjiv K)

员工数量261

证券类型Ordinary Share

年结日Jul 16

公司地址60 Hampshire Street

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02139

电话16173708837

网址https://relaytx.com/

公司代码RLAY

上市日期Jul 16, 2020

CEOPatel (Sanjiv K)

Relay Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Mark Murcko, Ph.D.

Independent Director

996.95K

--

Mr. Brian R. Adams, J.D.

Chief Legal Officer, Secretary

178.96K

-19913.00%

Mr. Peter (Pete) Rahmer

Chief Corporate Development Officer

120.71K

-13038.00%

Mr. Douglas S. (Doug) Ingram, Esq., J.D.

Independent Director

25.00K

--

Dr. Sanjiv K. Patel, M.D.

President, Chief Executive Officer, Director

--

Dr. Donald A. Bergstrom, M.D., Ph.D.

President - Research and Development

--

Mr. Thomas (Tom) Catinazzo

Chief Financial Officer

--

Mr. Alexis A. Borisy

Independent Chairman of the Board

--

Dr. Linda A. Hill, Ph.D.

Independent Director

--

Dr. Sekar (Sek) Kathiresan, M.D.

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Dr. Mark Murcko, Ph.D.

Independent Director

996.95K

--

Mr. Brian R. Adams, J.D.

Chief Legal Officer, Secretary

178.96K

-19913.00%

Mr. Peter (Pete) Rahmer

Chief Corporate Development Officer

120.71K

-13038.00%

Mr. Douglas S. (Doug) Ingram, Esq., J.D.

Independent Director

25.00K

--

Dr. Sanjiv K. Patel, M.D.

President, Chief Executive Officer, Director

--

Dr. Donald A. Bergstrom, M.D., Ph.D.

President - Research and Development

--

收入明细

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q3

FY2023

FY2022

FY2021

FY2020

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

0.00

0.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月18日周二

持股股东

股东类型

持股股东

占比

SB Investment Advisers (UK) Limited

16.10%

Commodore Capital LP

9.81%

Point72 Asset Management, L.P.

8.52%

Casdin Capital, LLC

6.54%

BlackRock Institutional Trust Company, N.A.

6.05%

其他

52.98%

持股股东

占比

SB Investment Advisers (UK) Limited

16.10%

Commodore Capital LP

9.81%

Point72 Asset Management, L.P.

8.52%

Casdin Capital, LLC

6.54%

BlackRock Institutional Trust Company, N.A.

6.05%

其他

52.98%

股东类型

持股股东

占比

Hedge Fund

36.60%

Investment Advisor

27.59%

Private Equity

16.70%

Investment Advisor/Hedge Fund

12.95%

Research Firm

2.08%

Individual Investor

1.27%

Venture Capital

0.91%

Sovereign Wealth Fund

0.48%

Family Office

0.38%

其他

1.05%

机构持股



更新时间: 1月1日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q4

458

170.00M

98.08%

-43.10M

2025Q3

457

168.31M

97.11%

-38.09M

2025Q2

460

180.78M

105.44%

-7.40M

2025Q1

473

175.15M

102.43%

-21.99M

2024Q4

463

170.97M

101.10%

-14.45M

2024Q3

455

166.81M

103.61%

+17.06M

2024Q2

434

132.20M

98.83%

-25.01M

2024Q1

423

138.51M

105.71%

-7.14M

2023Q4

410

132.38M

103.96%

-10.79M

2023Q3

396

136.20M

110.68%

-5.83M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

SB Investment Advisers (UK) Limited

27.90M

16.1%

--

Sep 30, 2025

Commodore Capital LP

17.00M

9.81%

+3.65M

+27.34%

Sep 30, 2025

Point72 Asset Management, L.P.

14.77M

8.52%

+1.33M

+9.88%

Sep 30, 2025

Casdin Capital, LLC

11.34M

6.54%

-57.19K

-0.50%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

10.48M

6.05%

-143.98K

-1.35%

Sep 30, 2025

The Vanguard Group, Inc.

9.37M

5.4%

+15.89K

+0.17%

Sep 30, 2025

Bellevue Asset Management AG

8.35M

4.82%

+114.74K

+1.39%

Sep 30, 2025

Tang Capital Management, LLC

8.07M

4.65%

--

Sep 30, 2025

State Street Investment Management (US)

5.07M

2.92%

-136.80K

-2.63%

Sep 30, 2025

Nextech Invest, Ltd.

3.85M

2.22%

--

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Virtus LifeSci Biotech Clinical Trials ETF

1.4%

Tema Oncology ETF

0.98%

ALPS Medical Breakthroughs ETF

0.51%

State Street SPDR S&P Biotech ETF

0.33%

ProShares Ultra Nasdaq Biotechnology

0.17%

Direxion Daily S&P Biotech Bull 3X Shares

0.16%

Avantis US Small Cap Equity ETF

0.14%

Invesco Nasdaq Biotechnology ETF

0.12%

Invesco RAFI US 1500 Small-Mid ETF

0.09%

iShares Biotechnology ETF

0.08%

Virtus LifeSci Biotech Clinical Trials ETF

占比1.4%

Tema Oncology ETF

占比0.98%

ALPS Medical Breakthroughs ETF

占比0.51%

State Street SPDR S&P Biotech ETF

占比0.33%

ProShares Ultra Nasdaq Biotechnology

占比0.17%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.16%

Avantis US Small Cap Equity ETF

占比0.14%

Invesco Nasdaq Biotechnology ETF

占比0.12%

Invesco RAFI US 1500 Small-Mid ETF

占比0.09%

iShares Biotechnology ETF

占比0.08%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据